Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares OutstandingShares Outstanding (Weighted Average)
Others
Ratios

Viking Therapeutics (VKTX) Income from Continuing Operations (2016 - 2025)

Viking Therapeutics (VKTX) has disclosed Income from Continuing Operations for 12 consecutive years, with 157703000.0 as the latest value for Q4 2025.

  • Quarterly Income from Continuing Operations fell 345.56% to 157703000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was 359638000.0 through Dec 2025, down 227.0% year-over-year, with the annual reading at 359638000.0 for FY2025, 227.0% down from the prior year.
  • Income from Continuing Operations hit 157703000.0 in Q4 2025 for Viking Therapeutics, down from 90789000.0 in the prior quarter.
  • In the past five years, Income from Continuing Operations ranged from a high of 12351000.0 in Q4 2021 to a low of 157703000.0 in Q4 2025.
  • Historically, Income from Continuing Operations has averaged 33958500.0 across 5 years, with a median of 20892500.0 in 2022.
  • Biggest five-year swings in Income from Continuing Operations: dropped 10.44% in 2023 and later crashed 345.56% in 2025.
  • Year by year, Income from Continuing Operations stood at 12351000.0 in 2021, then crashed by 58.29% to 19551000.0 in 2022, then decreased by 25.72% to 24579000.0 in 2023, then crashed by 44.0% to 35394000.0 in 2024, then tumbled by 345.56% to 157703000.0 in 2025.
  • Business Quant data shows Income from Continuing Operations for VKTX at 157703000.0 in Q4 2025, 90789000.0 in Q3 2025, and 65541000.0 in Q2 2025.